Microglia produce the amyloidogenic ABri peptide in familial British dementia
Open accessPreprint — published as 10.1007/s00401-024-02820-z · Paper page
The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
Mutations in ITM2B cause familial British, Danish, Chinese and Korean dementias. In familial British dementia (FBD) a mutation in the stop codon of the ITM2B gene (also known as BRI2 ) causes a C-terminal cleavage fragment of the ITM2B/BRI2 protein to be extended by 11 amino acids. This fragment, termed amyloid-Bri (ABri), is highly insoluble and forms extracellular plaques in the brain. ABri plaques are accompanied by tau pathology, neuronal cell death and progressive dementia, with striking parallels to the aetiology and pathogenesis of Alzheimer’s disease. The molecular mechanisms underpinning FBD are ill-defined. Using patient-derived induced pluripotent stem cells, we show that expression of ITM2B/BRI2 is 34-fold higher in microglia than neurons, and 15-fold higher in microglia compared with astrocytes. This cell-specific enrichment is supported by expression data from both mouse and human brain tissue. ITM2B/BRI2 protein levels are higher in iPSC-microglia compared with neurons and astrocytes. Consequently, the ABri peptide was detected in patient iPSC-derived microglial lysates and conditioned media but was undetectable in patient-derived neurons and control microglia. Pathological examination of post-mortem tissue support ABri expression in microglia that are in proximity to pre-amyloid deposits. Finally, gene co-expression analysis supports a role for ITM2B/BRI2 in disease-associated microglial responses. These data demonstrate that microglia are the major contributors to the production of amyloid forming peptides in FBD, potentially acting as instigators of neurodegeneration. Additionally, these data also suggest ITM2B/BRI2 may be part of a microglial response to disease, motivating further investigations of its role in microglial activation. This has implications for our understanding of the role of microglia and the innate immune response in the pathogenesis of FBD and other neurodegenerative dementias including Alzheimer’s disease.
Verification finished with gaps
Some checks didn’t finish. The results below cover the steps that did.
- Registry recordVerified
- Full textRead the full text
- Reference list81 references found
- Reference check81 of 81 references checked
- StatisticsRecomputed
- ClaimsDidn’t finish — the rest of the report still applies.
- Cited sourcesDidn’t finish — the rest of the report still applies.
- Self-checkChecked
- VerificationFindings verified
Overview
CoChat Summary
TL;DR
Using patient-derived iPSCs, this study finds that ITM2B/BRI2 is highly enriched in microglia and that FBD patient-derived microglia produce the amyloidogenic ABri peptide, while patient-derived neurons do not. Post-mortem FBD/FDD tissue and gene co-expression analyses further link ABri/ADan and ITM2B/BRI2 to microglial amyloid responses.
Key findings
- ITM2B/BRI2 expression was 34-fold higher in iPSC-derived microglia than in iPSC-derived neurons and 15-fold higher than in astrocytes in the abstract (the Results section reports 14-fold for astrocytes); this microglial enrichment was supported by mouse and human brain expression datasets.
- The 4 kDa ABri peptide was detected in patient iPSC-derived microglial lysates and conditioned media, but was undetectable in patient-derived neurons and control microglia.
- In post-mortem FBD and FDD hippocampus, ABri/ADan colocalized with microglial markers and Thioflavin-positive amyloid in proximity to pre-amyloid deposits.
- ITM2B/BRI2 co-expression networks from human AD/MCI microglial scRNA-seq were enriched for ARM/DAM genes including TREM2, TYROBP, C1QA, C1QB, CTSB, CTSS, LAMP2, and HLA genes; ITM2B and TREM2 were upregulated by IFNβ and downregulated by TNFα and LPS, with no significant basal inflammatory differences between control and FBD microglia.
Methods
- Patient-derived iPSCs from two FBD donors with the c.799 T>A mutation and control lines were differentiated into cortical neurons, astrocytes, and microglia-like cells; analyses included qPCR, Western blotting, immunocytochemistry, and siRNA knockdown of ITM2B/BRI2.
- Post-mortem hippocampal tissue from one FBD case and one FDD case was examined by immunohistochemistry, in situ hybridisation, and Thioflavin staining.
- Gene co-expression analysis used HumanBase, GeneFriends, and COXPRESdb, plus scRNA-seq microglia from AD and MCI dorsolateral prefrontal cortex with CoExpNets/WGCNA; microglia were treated with IFNβ, TNFα, or LPS.
Limitations
- The paper states that FBD is extremely rare, limiting the number of patient-derived iPSC lines and access to brain tissue; future work will use genome editing and expand to other ITM2B-linked dementias.
- The paper states that gene co-expression network analysis was performed on Alzheimer’s disease brain datasets rather than FBD tissue, and that iPSC neurons have a foetal-like transcriptome, so increased neuronal ITM2B expression at extended time points cannot be excluded.
- The paper states that other cell types, such as endothelial cells and oligodendrocytes, cannot be discounted as contributors to ABri production, especially given the high angiopathy burden; evident limitations include immunohistochemistry from one FBD and one FDD donor, non-quantitative in situ hybridisation, microglial batch variability, and an uncertain 25 kDa band in human brain samples.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4 ITM2B is coexpressed with ARM network genes and responds to inflammatory cues in a similar manner to TREM2. A Genetic network plot of a module containing ITM2B detected in microglial cells isolated from human Alzheimer’s disease patients and individuals with MCI analysed by scRNA-seq [44] demonstrating ITM2B is coexpressed with ARM network genes in microglia isolated from human individuals showing neurodegeneration (and collectively varying between AD and MCI donors). Genes varying in response to AD with the highest connectivity to ITM2B from the co-expression network were plotted based on ranking the connectivity matrix of the expression data. This module contains genes associated with the DAM/ARM state (the full network and the strength of each interaction is given in Supplementary Table 1). Genes most strongly co-expressed with ITM2B include genes known to be associated with neurodegeneration including LAPTM5, HLA genes, CTSB, CTSS, GRN, TREM2 and TYROBP. ITM2B is highlighted with a yellow oval. B, C qPCR expression analyses of ITM2B and TREM2 in response to a 24 h treatment with IFNβ and TNFα. Data represent n = 4 for untreated and IFNβ and n = 3 for TNFα, each from 2 independent batches of microglia and for two control iPSC lines and two FBD lines. Data separated by genotype is presented in Fig S8B. Paired t-tests were performed for each treatment relative to untreated samples, * = p < 0.05, ** = p < 0.01. D–I qPCR analyses of genes associated with microglial state changes under basal conditions. Data represent 6 ≤ n ≤ 11 from 3 independent batches of microglia](https://figures.cochat.ai/paper-figures/b2aec1fd542243918f3ebfc8aa441342/microglia-produce-the-amyloidogenic-abri-peptide-in-familial-british-dementia-figure-4.jpg)
Verification
Claims the paper makes
This check didn’t finish.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“15-fold higher in microglia compared with astrocytes”
“14-fold higher in microglia compared with astrocytes”
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citationA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
An anatomically comprehensive atlas of the adult human brain transcriptome
Hawrylycz, M. J., Lein, E. S., Guillozet-Bongaarts, A. L., Shen, E. H., Ng, L., Miller, J. A., van de Lagemaat, L. N., Smith, K. A., Ebbert, A., Riley, Z. L., et al. (2012) · Nature · doi:10.1038/nature11405 · Cited by 3,083
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Zhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., Vogel, H., Steinberg, G. K., Edwards, M. S. B., Li, G., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.013 · Cited by 2,295
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061
Molecular diversity and specializations among the cells of the adult mouse brain
Saunders, A., Macosko, E. Z., Wysoker, A., Goldman, M., Krienen, F. M., de Rivera, H., Bien, E., Baum, M., Bortolin, L., Wang, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.028 · Cited by 1,531
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.008 · Cited by 1,125
Research works printed but not linked: 1
- Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S et al (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34:11929–11947. 10.1523/JNEUROSCI.1860-14.2014 25186741 PMC4152602 · DOI · Paper page
Cited by
He, C., Chen, B., Yang, H., & Zhou, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1554398 · Cited by 48
Ziff, O. J., Jolly, S., Casey, J. M., Granat, L., Samra, S., Setó‐Salvia, N., Alatza, A., Phadke, L., Galet, B., Ravassard, P., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00864-7 · Cited by 10
Self-citationEvidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis
Hardy, J., & Lewis, P. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00847-8 · Cited by 3
Self-citationAhmad, W., Zhao, T., He, K., & Luo, S. (2023) · Supramolecular Materials · doi:10.1016/j.supmat.2023.100050 · Cited by 2
Choudhury, A., Yeşiltepe, M., Lashley, T., Singh, V., Minhas, V., Yin, T., Fernández, A., D'adamio, L., & Ahn, H. J. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03537-w · Cited by 2
Self-citationMajdič, G. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1815976 · Cited by 1
Gergian, C., Urbanaviciute, P., Wells, P. M., Transfeld, J. L., Askarova, A., Yaa, R. M., Wu, Y., Ziegler, K. C., Nickl, C. K., Pasillas, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.09.750356
Divergent consequences of PSEN1 knockout and PSEN2 knockout in stem cell derived models of the brain
Arber, C., Fernandez, M. B., Villegas-Llerena, C., Bruno, L., Crawford, S., Tomczuk, F., Lewis, P. A., Pocock, J. M., Hardy, J., & Wray, S. (2026) · Brain Communications · doi:10.64898/2026.04.09.717238
Self-citationHighlights from the first ITM2B Symposium
Alatza, A., Bruno, L., Crawford, S., Fernández, A., Houlden, H., Kim, K. W., Lasagna‐Reeves, C. A., Mead, S., Moreno-García, A., Hardy, J., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag449
Self-citation
Metadata
- Authors
- Arber, C., Casey, J. M., Crawford, S., Rambarack, N., Yaman, U., Wiethoff, S., Augustin, E., Piers, T. M., Rostagno, A., Ghiso, J., Lewis, P. A., Revesz, T., Hardy, J., Pocock, J. M., Houlden, H., Schott, J. M., Salih, D. A., Lashley, T., & Wray, S.
- Affiliations
- UCL Queen Square Institute of Neurology (GB)
- University College London (GB)
- University of Münster (DE)
- New York University (US)
- Royal Veterinary College (GB)
- Corresponding author
- Lashley, Tammaryn
- Wray, Selina
- ORCID
- Venue
- Acta Neuropathologica
- Publisher
- openRxiv
- Published
- 2023-06-28
- Volume
- 148
- Issue
- 1
- Pages
- 65-65
- ISSN
- 0001-6322 (ISSN-L)
- PMC
- PMC11568029
- OpenAlex
- W4404421557
- Cited by
- 9
- References
- 79
- Citations by year
- 2026: 4 · 2025: 4 · 2023: 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
- PubMed Central (submittedVersion)
- PubMed (submittedVersion)
- Funders
- European Federation of Pharmaceutical Industries and Associations
- Alzheimer's Society (AS‐JF‐18‐008)
- National Institute for Health and Care Research
- University College London
- European Commission (HORIZON2020, 115976)
- Alzheimer’s Research UK (ARUKSRF2016B-2)
- University College London Hospitals NHS Foundation Trust
- Innovative Medicines Initiative (115976)
- National Institutes of Health (RF1AG059695)
- Medical Research Council (MR/M02492X/1)
- Engineering and Physical Sciences Research Council (EP/N509577/1)
- UCLH Biomedical Research Centre
- National Institute on Aging (RF1 AG059695)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- familial British dementia, ITM2B, BRI2, microglia, amyloid plaques, induced pluripotent stem cell-derived microglia, tau pathology, neurodegeneration, microglial activation, Alzheimer's disease, innate immune response, gene co-expression
- MeSH terms
- Animals, Brain, Dementia, Humans, Neurons, Amyloid beta-Peptides, Microglia, Adaptor Proteins, Signal Transducing, Mice, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.